According to the announcement of Tianjin Pharmaceutical Pharmaceutical, the controlling shareholder of the pharmaceutical group, the indirect controlling shareholder of the company, the 100% shares of Shanghai Liuliguang, a shareholder holding 35% of the shares, will be listed and transferred. Shanghai Shangshi and Shangshi Investment hold 51% and 49% of Shanghai Liuliguang's shares respectively. The two publicly listed and transferred 100% of Shanghai Liuliguang's state-owned shares through the Shanghai Joint Stock Exchange. The information disclosure period is from September 24, 2026 to October 29, 2026. There is uncertainty about whether this equity listing transfer will be successful. The company will closely monitor the progress and fulfill its information disclosure obligations. Investors are kindly requested to pay attention to investment risks.

According to the announcement of Tianjin Pharmaceutical Pharmaceutical, the controlling shareholder of the pharmaceutical group, the indirect controlling shareholder of the company, the 100% shares of Shanghai Liuliguang, a shareholder holding 35% of the shares, will be listed and transferred. Shanghai Shangshi and Shangshi Investment hold 51% and 49% of Shanghai Liuliguang's shares respectively. The two publicly listed and transferred 100% of Shanghai Liuliguang's state-owned shares through the Shanghai Joint Stock Exchange. The information disclosure period is from September 24, 2026 to October 29, 2026. There is uncertainty about whether this equity listing transfer will be successful. The company will closely monitor the progress and fulfill its information disclosure obligations. Investors are kindly requested to pay attention to investment risks.